Clinical value of selected markers of angiogenesis, inflammation, insulin resistance and obesity in type 1 endometrial cancer
- PMID: 32977765
- PMCID: PMC7519537
- DOI: 10.1186/s12885-020-07415-x
Clinical value of selected markers of angiogenesis, inflammation, insulin resistance and obesity in type 1 endometrial cancer
Abstract
Background: It is a well-known fact show that the risk of developing endometrial cancer (type 1 EC) is strongly associated with obesity. In this study, selected markers, such as obesity, insulin resistance, angiogenesis and inflammation markers related to EC type 1 progression and patients' survival data were analyzed.
Methods: To measure levels of adiponectin, C-reactive protein (CRP), vascular endothelial growth factor-A (VEGF-A), angiopoietin-2 (Ang-2), insulin-like growth factor-1 (IGF-1), insulin and C-peptide in 176 preoperative serum samples, the immunoassay technique (EMIT) has been applied.
Results: Angiopoietin-2 levels increase with age (P = 0.005), FIGO stage (p = 0.042), myometrial invasion (P = 0.009) and LVSI (P < 0.001). The CRP levels increase with age (P = 0.01), as well as the advancement of the FIGO stage (P < 0.001), higher tumor grade (P = 0.012), and myometrial invasion (P < 0.001). A positive correlation between serum Ang-2 and CRP levels was demonstrated (r = 0.44; p < 0.001). Kaplan-Meier survival analysis showed that patients with high CRP levels in serum and Ang-2 presented a worse outcome (P = 0.03 and P = 0.015, respectively). Cox regression analysis of individual predictors revealed that high serum levels of Ang-2, CRP, advanced clinical FIGO stage (P < 0.001, respectively), old age (P = 0.013) were all significant overall survival predictors. By means of multivariate analysis, their predictive significance was confirmed.
Conclusion: Our study provides evidence that serum levels of Ang-2 and CRP may serve as predictors for assessment of the clinical stage of type 1 EC and are significantly associated with poor prognosis. It is likely that angiogenesis and inflammation associated with obesity have a significant impact on EC type 1 progression and survival rate of patients.
Keywords: Angiogenesis; Endometrial cancer; Inflammation; Insulin resistance; Obesity.
Conflict of interest statement
The authors have stated explicitly that there are no conflicts of interest in connection with this article.
Figures
Similar articles
-
Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer.Br J Cancer. 2011 Jan 4;104(1):51-9. doi: 10.1038/sj.bjc.6606005. Epub 2010 Nov 16. Br J Cancer. 2011. PMID: 21081932 Free PMC article.
-
[Clinical application of adult comorbidity evaluation-27 in endometrial cancer].Zhonghua Fu Chan Ke Za Zhi. 2016 Nov 25;51(11):810-817. doi: 10.3760/cma.j.issn.0529-567X.2016.11.003. Zhonghua Fu Chan Ke Za Zhi. 2016. PMID: 27916063 Chinese.
-
Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer.Gynecol Oncol. 2004 Apr;93(1):215-22. doi: 10.1016/j.ygyno.2003.12.031. Gynecol Oncol. 2004. PMID: 15047239
-
[Angiogenesis-prognostic factor in patients with endometrial cancer].Ginekol Pol. 2005 Oct;76(10):838-45. Ginekol Pol. 2005. PMID: 16417101 Review. Polish.
-
The Role of Obesity in the Etiology and Carcinogenesis of Endometrial Cancer.Cureus. 2024 Apr 28;16(4):e59219. doi: 10.7759/cureus.59219. eCollection 2024 Apr. Cureus. 2024. PMID: 38807790 Free PMC article. Review.
Cited by
-
C-Reactive Protein as a Prognostic Biomarker for Gynecologic Cancers: A Meta-Analysis.Comput Intell Neurosci. 2022 Oct 11;2022:6833078. doi: 10.1155/2022/6833078. eCollection 2022. Comput Intell Neurosci. 2022. Retraction in: Comput Intell Neurosci. 2023 Aug 9;2023:9864592. doi: 10.1155/2023/9864592. PMID: 36268143 Free PMC article. Retracted.
-
Circulating Adipocytokines and Insulin Like-Growth Factors and Their Modulation in Obesity-Associated Endometrial Cancer.Cancers (Basel). 2024 Jan 26;16(3):531. doi: 10.3390/cancers16030531. Cancers (Basel). 2024. PMID: 38339282 Free PMC article.
-
Associations of insulin resistance and inflammatory biomarkers with endometrial cancer survival: The Alberta endometrial cancer cohort study.Cancer Med. 2022 Apr;11(7):1701-1711. doi: 10.1002/cam4.4584. Epub 2022 Feb 16. Cancer Med. 2022. PMID: 35174651 Free PMC article.
-
Diagnostic and Therapeutic Values of Angiogenic Factors in Endometrial Cancer.Biomolecules. 2021 Dec 21;12(1):7. doi: 10.3390/biom12010007. Biomolecules. 2021. PMID: 35053155 Free PMC article. Review.
-
Pre-treatment inflammatory parameters predict survival from endometrial cancer: A prospective database analysis.Gynecol Oncol. 2022 Jan;164(1):146-153. doi: 10.1016/j.ygyno.2021.11.009. Epub 2021 Nov 19. Gynecol Oncol. 2022. PMID: 34802721 Free PMC article.
References
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. - PubMed
-
- Reports based on data of National Cancer Registry. The Maria Sklodowska-Curie Memorial Cancer Center. Department of Epidemiology and Cancer Prevention, National Cancer Registry. http://onkologia.org.pl/k/baza-on-line/. Accessed 23 Oct 2018.
-
- Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet. 2016;387(10023):1094–1108. - PubMed
-
- Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol. 2014;15(7):e268–e278. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous